Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report published on Thursday morning,Benzinga reports. They currently have a $15.00 price objective on the stock.

Other research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Stock Up 7.2 %

NASDAQ COYA opened at $7.00 on Thursday. Coya Therapeutics has a one year low of $4.75 and a one year high of $10.69. The company has a 50-day simple moving average of $5.87 and a 200-day simple moving average of $6.40.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. As a group, equities analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Arun Swaminathan acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the acquisition, the chief executive officer now owns 5,000 shares in the company, valued at approximately $36,700. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired 9,510 shares of company stock valued at $69,615 over the last ninety days. Corporate insiders own 9.80% of the company’s stock.

Institutional Trading of Coya Therapeutics

Large investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth $101,000. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics during the 3rd quarter valued at $169,000. Newbridge Financial Services Group Inc. acquired a new position in Coya Therapeutics during the 4th quarter valued at $401,000. Finally, Geode Capital Management LLC raised its stake in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.